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We have developed an alternative to transgenesis for producing
antigen-specific T cells in vivo. In this system, clonal naive T cells
with defined antigen specificity are generated by retrovirus-
mediated expression of T cell antigen receptor cDNAs in RAG1-
deficient murine hematopoietic precursor cells. These T cells can be
stimulated to proliferate and produce cytokines by exposure to
antigen in vitro, and they become activated and expand in vivo
after immunization. IL-2-deficient T cells generated by this tech-
nique show decreased proliferation and cytokine production, both
of which can be rescued by exogenous addition of this growth
factor. Thus, retrovirus-mediated expression of T cell antigen
receptor cDNAs in hematopoietic precursor cells permits the rapid
and efficient analysis of the life history of antigen-specific T cells
in different genetic backgrounds and may allow for the long-term
production of antigen-specific T cells with different functional
properties for prophylactic and therapeutic purposes.
T cells provide protection against infections and tumors byrecognizing peptides presented on major histocompatibility
molecules using a highly specific antigen receptor, the T cell
receptor (TCR; refs. 1–4). The genetic template for this receptor
is created during T cell development in the thymus by the V(D)J
DNA rearrangement process, which imparts a unique antigen
specificity on each TCR (5–7). The TCR plays an essential role
in T cell function, development, and survival. Genetic lesions
that interfere with the generation of antigen receptors block T
cell development and result in immunodeficiencies (8–10). By
defining the specificity of pathogenic T cells, TCRs also are
involved centrally in the initiation of autoimmunity and allergies
(11, 12).
Because TCRs play such a critical role in T cell development
and function, much has been learned about the life history of T
cells and the immune responses that they elicit by studying the
composition and function of these antigen receptors. The ability
to generate mice that express a specific TCR on most T cells by
transgenesis has enabled the study of T cell development and
function in vivo (13–20). It has also made possible the creation
of antigen-specific animal models of many important immuno-
logical diseases (18, 21, 22). The first successful strategy to
generate TCR transgenic mice involved pronuclear injection of
large fragments of genomic DNA encoding the rearranged  and
 chains of the TCR (20). In these mice, the expression of the
TCR was driven by the homologous promoter and enhancer
elements. Subsequent studies have demonstrated that it is pos-
sible also to generate TCR transgenic mice expressing constructs
that use heterologous promoters that can be either T cell-
specific, such as the CD2 promoter (23), or nonspecific, such as
the MHC class I promoter, which is expressed in all nucleated
cells (17). In TCR transgenic mice that use promoters with
activity that is not restricted to T cells, TCR and TCR chains
are found in other cell types. However, these proteins are
displayed only on the plasma membrane in T cells, because these
are the only cells that express CD3, a protein complex required
for surface expression of TCRs (24).
Recently a number of groups have shown that functional
expression of a TCR can be obtained in mature T cells by using
retroviral vectors to carry DNA into these cells (25–29). In these
studies, TCR and TCR genes were introduced and stably
expressed in T cells that had been activated with a mitogen. By
using this approach, T cells derived from nonspecific, heteroge-
neous populations were converted into antigen-specific T cells
capable of responding to protein antigens and tumors (25–29).
These results suggest that transgenic expression of TCRs might
be used not only to study T cell function but also as a therapeutic
strategy to generate antigen-specific T cells capable of targeting
tumor antigens and infectious agents.
Although retrovirus-mediated expression of TCR genes shows
promise as a strategy to produce antigen-specific T cells, the
published approaches have certain limitations. The T cells that
are engineered to express TCRs are activated mature cells that
already express an endogenous TCR of unknown specificity.
Their effector function may be restricted by the conditions under
which they are activated in vitro, and it is unclear how long they
persist in vivo (30, 31). To attempt to overcome these problems,
we have tested whether it is possible to generate naive antigen-
specific T cells by expressing TCR and TCR genes in hema-
topoietic precursor cells derived from RAG1-deficient mice
using retroviruses and then injecting these cells into irradiated
mice to reconstitute their T cell population. We report here that
this approach has been successful, and that T cells produced in
this manner respond normally to antigen challenge both in vitro
and in vivo. Furthermore, we demonstrate that this strategy can
be used to generate T cells with different functional properties
by expressing TCR and TCR genes in hematopoietic cells
from wild-type and IL-2 knockout mice. Our results demonstrate
that retrovirus-mediated expression of TCR genes in hemato-
poietic precursor cells provides an efficient and rapid new
approach for generating antigen-specific T cells that can be used
for basic research and might be valuable in the clinic.
Materials and Methods
Mice. C57BL6 (B6) mice were purchased from Charles River
Breeding Laboratories, and RAG1 and IL-2 knockout mice were
purchased from The Jackson Laboratory. IL-2RAG1 double-
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knockout mice were generated by breeding. All mice were
housed in the California Institute of Technology animal facility
according to institute regulations.
MIG-TCR Retroviruses Construction. The generation of the MIG
[murine stem cell virusinternal ribosome entry sitegreen fluo-
rescent protein (GFP)] retroviral expression vector has been
described before (32). OTII TCR cDNA and OTII TCR
cDNA were cloned separately into MIG. Retroviruses were
generated by transfecting HEK293 T cells using a standard
calcium phosphate precipitation technique (33). Viruses were
harvested 48 and 72 h after transfection.
Generation of the THZ Hybridoma Cell Line and Infection with Retro-
viruses. Activated mouse CD4 T cells were fused with the BWZ
cell line, which contains a reporter gene (lacZ) that is expressed
under the control of the nuclear factor of activated T cells
(NFAT) elements of the human IL-2 promoter by standard
methodology (34). The resulting T cell hybridomas were cloned
by limiting dilution. One specific clone, named THZ, lacked
TCR expression but still maintained CD3 and CD4 expression.
It was sorted by flow cytometry three times to stabilize the
TCR-CD3CD4 phenotype. THZ has allowed us to test sur-
face expression and specificity of TCRs by assaying antigen
responses using a lacZ assay.
THZ cells expressing the OTII TCR were generated by spin
infection with both MIGOTII and MIGOTII retroviruses
in the presence of 10 gml polybrene for 90 min at 2,500 rpm
at 30°C using a Beckman Allegra 6R centrifuge. The efficiency
of infection was determined by assaying GFP fluorescence by
flow cytometry. The response of THZ OTII cells to residues
323–339 of chicken ovalbumin (OVAp) was assayed by stimu-
lating these cells with OVAp and B6 spleen cells overnight. The
next day, TCR signaling was measured by lacZ assay.
Bulk LacZ Assay. THZ OTII cells were cultured in 96-well plates,
washed once with PBS, lysed, and exposed to the colorogenic
-galactosidase substrate, chlorophenol red -galactoside (Cal-
biochem), in 100 l of Z buffer (100 mM 2-mercaptoethanol9
mM MgCl20.125% Nonidet P-40 in PBS) and incubated at 37°C
overnight. The development of the colored lacZ product was
assayed by using a plate reader with a 570-nm filter and a 630-nm
filter for reference.
Primary CD4 T Cell Infection and Stimulation. To obtain CD4 T
cells, splenocytes were harvested from B6 mice. CD8 T cells
were depleted by using Dynabeads against mouse CD8 (Dynal,
Oslo) according to manufacturer instructions. CD4 T cells and
spleen antigen-presenting cells (APCs) then were cultured at 2
106 per ml in the presence of 0.5 gml anti-CD3 (PharMingen)
for 3 days. On days 1 and 2, the cells were spin-infected with both
MIGOTII and MIGOTII retroviruses in the presence of 5
gml polybrene for 90 min at 2,500 rpm at 30°C. After each
infection, the retroviral supernatant was replaced. On day 3, the
cells were collected, and some were used to assay the expression
of OTII TCR by flow cytometry. The rest were cultured ON
with 40 unitsml IL-2 (BioSource International, Camarillo, CA)
at 1  106 cells per ml. The next day, the rested cells were tested
for their responsiveness to OVAp by culturing them at 2  105
cells per well in a 96-well plate with 2  105 cells per well of
irradiated B6 spleen cells as APCs in T cell culture medium
containing OVAp at 0–10 gml. Three days later, [3H]thymi-
dine was added to the wells at 0.01 mCiml (1 Ci  37 GBq)
followed by ON culture. The proliferation of the cells was
analyzed with a Wallac (Gaithersburg, MD) 3H counter.
Bone Marrow (BM) Precursor Cell Isolation, Infection, and Transfer.
RAG1 knockout mice in a wild-type or IL-2 knockout back-
ground were treated with 250 gg of body weight of 5-f lurou-
racil (Sigma) dissolved in PBS. BM cells were harvested 5 days
later from the tibia and femur and cultured for 5 days at 2  106
cells per ml with 20 ngml recombinant mouse IL-3, 50 ngml
recombinant mouse IL-6, and 50 ngml recombinant mouse stem
cell factor (SCF) (all from Biosource International) in DMEM
containing 10% FCS. After 48–72 h, the BM cells were spin-
infected with a mixture of MIGOTII and MIGOTII retro-
viruses supplemented with 8gml polybrene for 90 min at 2,500
rpm at 30°C. After infections, the retroviral supernatant was
replaced. Recipient RAG1 mice of desired genetic back-
ground received a total of 480 rads of whole-body radiation and
then were injected intravenously with 1–2  106 infected BM
cells. BM-recipient mice were maintained on the mixed antibi-
otic sulfamethoxazole and trimethoprim oral suspension (Hi-
Tech Pharmacal, Amityville, NY) in a sterile environment for
6–11 weeks until analysis.
Immunization of BM-Recipient Mice. Ten weeks after irradiation
and receiving BM, mice were immunized by intraperitoneal
injection of 200 g of OVAp in PBS and then left for 6 days until
analysis.
In Vitro T Cell Stimulation and Proliferation Assays. Spleen cells from
BM-recipient mice were harvested and cultured at 2  105 cells
per well in a 96-well plate with 2  105 cells per well irradiated
B6 spleen cells as APCs in T cell culture medium containing
OVAp at 0–10 gml. Three days later, culture supernatants
were collected and assayed for IL-2 and IFN- levels by ELISA.
Proliferation was assessed by [3H]thymidine incorporation.
IL-2 and IFN- ELISA. ELISA plates (96-well) were coated with 50
l per well of 1 gml anti-mIL-2 or anti-mIFN- antibody
(PharMingen) in carbonate buffer for 2 h at 37°C. The plates
then were washed twice with PBS, blocked by adding 100 l per
well of dilution buffer [2% borate buffered saline (BBS)0.002%
sodium azide], and incubated for 30 min at 37°C. After being
washed four times with PBS, sample supernatants were added to
the plates at a final volume of 50 l per well and incubated for
3 h at 37°C. The plates were then washed four times followed by
the addition of 50 l per well of 1 gml of the detecting
biotinylated antibody (PharMingen) in dilution buffer and in-
cubated for 45 min at room temperature. The plates were then
washed six times with PBS, followed by addition of 50 lwell of
the Avidin-Alkaline Phosphotase (PharMingen) at a dilution of
1:400 in dilution buffer. The plates were then incubated for 30
min at room temperature. Finally, the plates were washed six
times with PBS. Developing solution Sigma 104 phosphatase
substrate (Sigma) was made up at 1 mgml in DEA buffer right
before use and then added at 50 l per well. Absorbance was
assayed by using a plate reader with a 405-nm filter.
Results
Functional Expression of the OTII TCR in T Cell Lines and Primary CD4
T Cells Using Retroviruses. We previously generated a bicistronic
retroviral expression vector MIG that allows efficient expression
of genes in primary cells of hematopoietic origin (32). This
retroviral vector expresses both GFP, to mark infected cells, as
well as a test gene. To examine whether we could use retroviruses
to functionally express TCRs in T cell populations, we cloned the
OTII TCR or TCR chain cDNAs into MIG (Fig. 1A). The
OTII TCR is a well defined class II MHC-restricted TCR that
responds to residues 323–339 of chicken ovalbumin (35). MIG
retroviruses expressing the cDNA for the OTII TCR or OTII
TCR chains were used to coinfect the THZ hybridoma line.
This cell line expresses CD3, and thus it can express TCRs on its
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surface. It also contains a reporter gene (lacZ) that is expressed
under the control of the NFAT element of the human IL-2
promoter and can be used to assay TCR signaling (30). The
infected THZ cells (marked by GFP fluorescence) expressed the
 chain of the OTII TCR at the cell surface (Fig. 1B Left) and
expressed the lacZ reporter gene when stimulated with OVAp
presented by APCs (Fig. 1C Left), indicating that we had
achieved functional expression of TCR in this hybridoma line.
We next tested whether we could express the OTII TCR in
primary T cells by using retroviruses. In these experiments,
purified CD4 T cells from wild-type C57BL6 mice were
activated with an antibody to CD3 and infected with MIG
OTII and MIG OTII viruses. The infected T cells (marked by
GFP fluorescence) expressed the  chain of the OTII TCR at the
cell surface (Fig. 1B Right) and proliferated when cultured with
OVAp presented by APCs (Fig. 1C Right), indicating that we had
achieved functional expression of TCR in primary CD4 T cells.
Generation of OTII TCR Monospecific T Cells in Vivo After Retrovirus-
Mediated Gene Delivery into BM Precursor Cells. We previously
developed a strategy to infect BM precursor cells with the MIG
retrovirus (36). To test whether it is possible to generate
functional T cells by expressing TCRs in these cells, we harvested
BM from wild-type and IL-2 knockout RAG1-deficient mice and
infected them with retroviruses expressing OTII and OTII.
These cells were injected into lethally irradiated RAG1-deficient
recipient mice and allowed to reconstitute their immune system,
thus producing OTII-monospecific mice (Fig. 2).
To determine whether retrovirus-mediated expression of the
OTII TCR could drive T cell development, we harvested and
stained thymocytes 11 weeks after the mice received BM cells.
The first indication that T cell development had been rescued
was that the cellularity of the thymi derived from mice expressing
OTII and OTII chains was increased greatly compared with
that from control mice that received BM precursor cells infected
with the empty MIG vector (data not shown). As shown in Fig.
3A, the majority (80%) of cells in the thymi of mice receiving
OTII-expressing cells were GFP-positive. These thymocytes
showed the expected distribution of CD4 and CD8 markers for
a developing class II-restricted T cell. Consistent with the
absence of endogenous TCRs, all mature T cells in the thymus
were CD4 single-positive. The development of OTII T cells was
identical in wild-type and IL-2-deficient backgrounds, support-
ing the notion that IL-2 is not required for CD4 T cell
development (37–39).
We also tested whether there were mature CD4 T cells in the
peripheral lymphoid organs of the OTII-monospecific mice.
From 30 to 60% of the cells in the lymph nodes and spleens (data
not shown) of these mice were GFP-positive (Fig. 3B). More than
80% of these cells were mature CD4 T cells that expressed the
OTII V element, V5. Similar results were observed in both
wild-type and IL-2-deficient backgrounds. These observations
demonstrated that retrovirus-mediated expression of TCR
cDNAs in BM precursor cells could drive normal T cell
development.
To determine the kinetics with which monospecific T cells
populated recipient mice after BM transfer, we performed a
time-course experiment. The earliest time point at which we
observed mature (CD4 single-positive) T cells in the thymus of
recipient mice was 6 weeks after reconstitution (data not shown).
However, no T cells were detectable in the peripheral lymphoid
organs of these mice at this time. At 8 weeks we started to
observe small numbers of monospecific CD4 single-positive T
cells in the lymph nodes and spleen. These cells were able to
respond to OVAp, indicating that they were mature. By 10–11
weeks the reconstitution of the T cell compartment was com-
Fig. 1. Functional expression of the OTII TCR in a T cell hybridoma line and
primary CD4 T cells using retroviruses. (A) Schematic representation of the
MIG retrovirus construct expressing the cDNA for the OTII TCRor TCR chain.
LTR, long terminal repeat; IRES, internal ribosomal entry site. (B) Surface
expression of the OTII TCR chain in infected (GFP) THZ cells (Left) and
primary CD4 T cells (Right). Cells were coinfected with MIG retroviruses
expressing the cDNA for the OTII TCR or OTII TCR chain and then stained
with an antibody against TCR V5, which is the V element used by the OTII
TCR chain. (C) Functional expression of the OTII TCR in THZ cells (Left) and
primary CD4 T cells (Right). Cells were coinfected with MIG retroviruses
expressing OTII TCR chain or OTII TCR chain and restimulated for 48 h with
OVAp in the presence of B6 spleen cells as APCs. Antigen responses were
evaluated by assaying the induction of-galactosidase expression for THZ cells
and by [3H]thymidine incorporation for primary CD4 T cells.
Fig. 2. Strategy to generate OTII monospecific T cells in vivo using retrovi-
ruses. Hematopoietic precursor cells are obtained from wild-type and IL-2-
deficient RAG knockout mice that have been treated with 5-fluorouracil.
These cells then are cultured in the presence of cytokines and coinfected with
MIG retroviruses expressing the cDNA for the OTII TCR or OTII TCR chain.
The infected hematopoietic precursor cells then are transferred into a lethally
irradiated host mouse and allowed to reconstitute the immune system. Ret-
rovirally transduced cells are identified by their expression of the GFP.
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plete, and substantial numbers of functional OTII T cells were
detectable in all lymphoid organs analyzed.
Normal in Vitro and in Vivo Antigen Responses of OTII TCR Monospe-
cific T Cells. To test whether the mature T cells present in
OTII-monospecific mice were functional, we stimulated cells
from lymph nodes and spleens derived from wild-type and IL-2
knockout mice with increasing concentrations of OVAp. OTII T
cells derived from wild-type mice proliferated and secreted IL-2
when stimulated with OVAp (data not shown). IL-2 knockout
OTII T cells did not secrete IL-2 or the effector cytokine IFN-
after antigen stimulation and showed a weak proliferative re-
sponse to antigen (Fig. 3C). The addition of exogenous IL-2
rescued proliferation and cytokine production (Fig. 3C). These
results demonstrate that the mature T cells found in OTII-
monospecific mice are functionally normal, and T cells with
defined genetic lesions exhibit the expected effects of this
mutation.
In the final set of experiments, we analyzed the response of
OTII-monospecific T cells to antigen stimulation in vivo by
immunizing mice with OVAp. Cells from the lymph nodes and
spleen were harvested 6 days later and counted, stained with
antibodies to activation markers, and restimulated in vitro. In
both the wild-type and IL-2-deficient backgrounds, there was a
significant increase in T cell number after immunization (Fig.
4A). The accumulating cells expressed surface markers typical of
activated T cells (CD62Llow and CD44high; Fig. 4A; refs. 40 and
41). Interestingly, we noticed that immunization led to a pref-
erential expansion of GFPhigh cells (Fig. 4B). Because the
expression of GFP correlates with the expression of TCR in our
vector system (32), this indicates that antigen exposure selects for
T cells that express higher levels of TCR in the mice. After
restimulation with OVAp in vitro, wild-type OTII T cells from
immunized mice proliferated vigorously and secreted the effec-
tor cytokine, IFN- (Fig. 4C). As expected, immunized IL-2-
deficient T cells showed reduced proliferation and IFN- pro-
duction unless exogenous IL-2 was added to the cultures (Fig.
4C). These results demonstrated that retrovirus-mediated ex-
pression of TCR cDNAs in BM precursor cells can give rise to
functionally mature T cells with different genetic backgrounds
that respond normally to antigen exposure in vivo.
Discussion
We report here a strategy to generate functional antigen-specific
T cells by expressing TCR and TCR chain cDNAs in RAG1-
deficient hematopoietic precursor cells using a retrovirus-based
vector and then injecting the cells into lethally irradiated host
mice. The T cells that develop in these mice respond normally to
peptide antigen when stimulated in vitro and can be expanded
and activated in vivo by immunization. Our approach allows the
rapid and efficient generation of antigen-specific T cells in
different genetic backgrounds and provides a tool for studying T
cell function. It may be possible to adapt this strategy to generate
T cells with prophylactic and therapeutic value.
TCR-Expressing Retroviruses Drive T Cell Development. The ability to
impart on T cells a defined antigen specificity by transgenic
expression of TCR genes has proven extremely valuable as an
approach for studying the immune system. Traditionally, this feat
has been accomplished by injecting linear DNA fragments that
express TCR and TCR genes under the control of homolo-
gous or heterologous promoters into the nuclei of embryos.
Recent studies have shown that it is possible also to functionally
express TCRs directly in mature T cells by using retroviruses.
This finding suggests that TCR transgenesis might be used for
therapeutic as well as scientific applications.
Our current findings demonstrate that it is possible to obtain
functional antigen-specific T cells in vivo by retrovirus-mediated
expression of TCR and TCR cDNAs in hematopoietic pre-
cursor cells. We accomplished this by using a well-studied
retroviral vector, based on the murine stem cell virus (42). The
advantage of the murine stem cell virus is that it maintains
long-term and stable expression in hematopoietic precursor cells
and their differentiated progeny (43). Importantly, the levels of
TCR and TCR cDNAs obtained from this vector in the T cell
compartment are sufficiently high to drive T cell development
and function. We have detected large numbers of mature
antigen-specific T cells up to 3 months after injection of infected
hematopoietic precursor cells. Because these cells are derived
from long-lived progenitor cells, it is likely that they will be
generated continually and persist for many months, possibly even
for the lifetime of the mouse (36). Previous attempts to generate
monospecific T cell populations by using other oncoretrovirus-
based vectors have failed to show detectable or functional
Fig. 3. Development of functional wild-type and IL-2-deficient OTII mono-
specific T cells derived from retrovirally transduced hematopoietic precursor
cells. (A) Normal thymic development of OTII monospecific CD4 T cells in
lethally irradiated mice receiving retrovirally transduced hematopoietic pre-
cursor cells. Thymocytes obtained from lethally irradiated host mice 11 weeks
after injection of retrovirally transduced hematopoietic precursor cells were
stained with antibodies to CD4 and CD8 and analyzed by flow cytometry. The
distribution of CD4 and CD8 expression on GFP thymocytes is shown. (B)
Presence of mature OTII monospecific CD4 T cells in the peripheral lymphoid
organs of mice receiving retrovirally transduced hematopoietic precursor
cells. Lymph node (LN) and spleen (data not shown) cells obtained from
lethally irradiated host mice 11 weeks after injection of retrovirally transduced
hematopoietic precursor cells were stained with antibodies to CD4 and TCR
V5 and analyzed by flow cytometry. The distribution of CD4 and TCR V5
expression on GFP lymph node cells is shown. (C) Normal functional responses
of OTII monospecific CD4 T cells obtained from the peripheral lymphoid
organs of mice receiving retrovirally transduced hematopoietic precursor
cells. Spleen cells obtained from lethally irradiated host mice 11 weeks after
injection of retrovirally transduced hematopoietic precursor cells derived
from IL-2-deficient mice were supplemented with B6 spleen cells as APCs and
stimulated in vitro with OVAp in the presence or absence of exogenous IL-2.
Proliferation was assayed after 72 h by [3H]thymidine incorporation and
cytokine production by ELISA. The data were normalized for the number of
GFPCD4TCR V5 cells present in the starting spleen cell populations.
Proliferation and cytokine production were seen with wild-type OTII T cells
both in the presence and absence of IL-2 (data not shown). N.D, not
determined.
Yang et al. PNAS  April 30, 2002  vol. 99  no. 9  6207
IM
M
U
N
O
LO
G
Y
expression of these receptors, presumably because the vectors
were silenced during hematopoietic development (40).
The only significant drawback of the retroviral vectors that we
have used in this study is that they can only introduce DNA into
cells that are proliferating. Hematopoietic stem cells usually are
quiescent. To induce them to proliferate, they have to be
harvested from mice that have been treated with the cytotoxic
agent 5-fluorouracil and then cultured with cytokines in vitro. In
contrast, lentivirus-based vectors are able to express genes in
noncycling cells (44). We recently developed protocols to express
TCR genes in unmanipulated hematopoietic precursor cells by
using well defined HIV-derived vectors (data not shown).
Use of Retroviruses to Study T Cell Development and Function.
Traditional TCR transgenic mice are designed to express a
complex genomic fragment of the TCR and TCR locus, not
the cDNA for these genes (45). In fact, transgenic mice have
been created with the TCR and TCR cDNAs for the OTII
TCR that we use here, but they did not show surface expression
of this TCR or produce any OTII T cells (35). It is thought that
genomic fragments produce better-regulated expression of
TCRs, leading to more efficient generation of transgenic T cells.
The fact that we have been successful with cDNAs may reflect
the circumstance that in each experiment we generate a large
number of hematopoietic precursor cells that express TCR genes
at different levels. Any individual retrovirus transgenic mouse
receives 1 million of these cells. It is likely that during thymic
development only those progenitor cells that express an appro-
priate amount of TCR proteins give rise to mature T cells.
Supporting the idea that populations of T cells can be selected
on the basis of the level of TCR that they express in our
monospecific T cell mice, we observed that immunization led to
an increase in GFPhigh (TCRhigh) cells. It is likely that the limited
amount of cognate peptide antigen present in immunized mice
led to a preferential expansion of T cells expressing high amounts
of the OTII TCR.
The available data suggest that neither transgenic nor retro-
virus-mediated expression of TCRs faithfully reproduce the
patterns of endogenous TCR expression. How this impacts the
development of T cells remains unclear. However, a growing
body of anecdotal and direct evidence suggests that the timing
and level of TCR expression plays an important role in deter-
mining the fate of a T cell (46–50). New retroviruses that drive
expression of genes under the control of tissue-specific and
regulated promoters should provide a novel and efficient tool to
address this important question in T cell biology further (44).
An additional advantage of using retroviruses to study T cell
development is that they can be used to introduce TCR genes
into hematopoietic stem cells derived from mice of different
genetic backgrounds or with defined genetic lesions, which has
enabled us to generate antigen-specific T cells that are deficient
for IL-2, and should allow the rapid and efficient evaluation of
genetic effects more generally on the development and function
of antigen-specific T cells.
Therapeutic and Prophylactic Uses of Retrovirus-Generated T Cells. As
well as providing a tool for studying T cell biology and immune
responses, our approach to generate antigen-specific T cells with
defined functional properties might be applied in a clinical
setting. Most importantly, our approach allows the production of
large numbers of naive T cells for prolonged periods of time.
These cells can be activated into effector T cells both in vitro and
in vivo by using a known peptide antigen. By expressing TCRs
with the appropriate antigen specificity, these T cells might
provide protection against infectious diseases such as HIV
AIDS and cancers. Alternatively, they could be used to regulate
the development of allergies and autoimmune diseases.
The TCR monospecific T cells generated in this study were
Fig. 4. In vivo responses of wild-type and IL-2-deficient OTII monospecific T cells
after immunization with cognate antigen. (A) T cell expansion and expression of
activation markers after immunization. Lethally irradiated host mice were im-
munized via an intraperitoneal injection of 200 g of OVAp (Immunized) or left
untreated(NoTX)10weeksafterreceivingretrovirally transducedhematopoietic
precursor cells. Spleen and lymph node cells were harvested and counted 6 days
later. An aliquot of these cells was stained with antibodies to CD4 and TCR V5,
CD62L, or CD44 and analyzed by flow cytometry. The number of OTII monospe-
cific T cells present in the spleen and lymph nodes of immunized and control mice
was determined by multiplying the percentage of GFPCD4TCR V5 cells by
the total number of cells present in these organs. The frequency of activated T
cells was determined by gating on GFPCD4TCR V5and CD62Llow or CD44high
cells. (B) Preferential expansion of GFPhigh OTII monospecific CD4 T cells after
immunization. Mice receiving retrovirally transduced hematopoietic precursor
cells were immunized as described for A. Spleen and lymph node cells were
collected and stained with antibodies to CD4 and TCR V5 and analyzed by flow
cytometry. The expression of GFP in V125CD4OT.II T cells and the frequency
of GFPhigh OTII T cells are shown. (C) Effector function of OTII monoclonal CD4
T cells after immunization. Mice receiving retrovirally transduced hematopoietic
precursor cells were immunized as described for A. Spleen cells were harvested
and stimulated in vitro with OVAp in the presence of B6 spleen cells as APCs.
Proliferation was assayed by [3H]thymidine incorporation, and cytokine produc-
tion was assayed by ELISA. The data were normalized for the number
of GFPCD4TCR V5 cells present in the starting populations. N.D., not
determined.
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derived from hematopoietic precursor cells deficient in the
RAG1 gene. These cells were used because they produce lym-
phoid cells that fail to express endogenous TCR chains. Such
endogenous proteins might compete with the retrovirally ex-
pressed TCR for surface expression and reduce the efficiency
with which antigen-specific T cells were generated. Although our
study shows that transgenic T cells can be generated readily from
RAG1-deficient progenitor cells, it would be useful, as a model
for potential human therapeutics, to be able to generate these
cells with wild-type cells as well. We already have been able to
generate T cells expressing a defined TCR chain by retrovirus-
mediated gene expression in wild-type hematopoietic precursor
cells (data not shown). It will also be informative to test whether
it is possible to generate transgenic T cells by injecting infected
progenitor cells into untreated mice or mice that receive my-
eloablative treatments that are less severe than whole body
irradiation. These treatments are less likely to produce long-
lasting damage to the host and more closely resemble protocols
that might be used in humans. Similar approaches have been
developed by using autologous hematopoietic stem cells to
produce long-term microchimerism that permits the transplan-
tation of immunologically incompatible organs (51).
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